DIRS.INFO The most relevant business & tech news

☆ Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stock
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Jefferies thinks its time for investors to go long on Pfizer . "In our view, PFE has one of the most intriguing catalyst paths over the next yr in large cap pharma and trades ~15% below where it traded at the start of the COVID pandemic." The analyst added Pfizer has already presented "an impressive innovation framework" that has helped the company adapt to healthcare headwinds, which underpinned the bullish long-term view. "During the pandemic, Pfizer in collaboration with Biontech rolled out COVID vaccines in a historical timeframe. PFE YTD mountain Pfizer stock YTD — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Akash Tewari, it's, Tewari, PFE, Biontech, Paxlovid, Michael Bloom Organizations: Pfizer, pharma

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products. Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook. Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023. Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Persons: Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru

☆ Stocks making the biggest moves premarket: Pfizer, Lululemon, Manchester United, Rite Aid and more
▼ + stars: | 2023-10-16 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Pfizer , Moderna , BioNTech — Shares of Pfizer dropped 1.3% after the company slashed its full-year revenue guidance by $9 billion, noting waning demand for its Covid treatment and vaccine. Following the guidance cut, Jefferies upgraded Pfizer on Monday, citing an attractive buying opportunity. Vaccine markers Moderna and BioNTech also dropped premarket, losing 4.1% and 5%, respectively. Colgate-Palmolive — The consumer products stock gained more than 1% in premarket trading after Stifel upgraded Colgate-Palmolive to buy from hold. The firm cited the stock's attractive valuation and the rapid and profitable growth of TAL's non-academic tutoring business as catalysts.

Persons: Jefferies, BioNTech, premarket, Morgan Stanley, Jim Ratcliffe, Jeffrey Stein, Dow, Charles Schwab, CNBC's Hakyung Kim, Jesse Pound, Tanaya Macheel, Michelle Fox Theobald, Lisa Han Organizations: Pfizer, Moderna, BioNTech, Colgate, Palmolive, Manchester United, Wall Street, . Rite, Dow Jones, Activision, Microsoft, TAL Education Group, UBS Locations: New Jersey

☆ Pfizer slashes revenue forecast on lower COVID sales, will cut costs
▼ + stars: | 2023-10-13 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Pfizer and rivals have begun selling an updated COVID vaccine for this fall. The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from its prior forecast of $67 billion to $70 billion. It had previously expected Paxlovid revenue of about $8 billion for the year. Pfizer also cut full-year revenue expectations for the COVID vaccine by about $2 billion due to lower-than-expected vaccination rates. Pfizer said its non-COVID products remain on track to achieve 6% to 8% revenue growth year over year in 2023.

Persons: Albert Boura, Michael Erman, Sriparna Roy, Bill Berkrot, Rod Nickel Organizations: Pfizer, U.S ., Strategic, Thomson Locations: York, New Jersey, Bengaluru

☆ Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump
▼ + stars: | 2023-10-13 | by ( Jacob Pramuk | ) www.cnbc.com time to read: +1 min

Pfizer slashed its full-year earnings and revenue guidance on Friday, as it said demand for its Covid products has waned. The company now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion. Pfizer said it cut its revenue outlook "solely due to its Covid products." The biopharmaceutical company slashed its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share, from a previous $3.25 to $3.45 per share. It also said it anticipates sales of its vaccine, Comirnaty, will be $2 billion lower than previously expected because of lower-than-expected vaccination rates.

Persons: Albert Bourla Organizations: Pfizer, European Commission, BioNTech, U.S ., CNBC, YouTube Locations: U.S, Puurs, Belgium

☆ Over 7 million Americans have gotten updated COVID vaccines
▼ + stars: | 2023-10-12 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Millions of doses of another updated COVID vaccine from Novavax (NVAX.O) have also been made available to Americans this week, according to the company. Last year's booster targeting the original virus and another variant was rolled out about 10 days earlier. By Sept. 28, 2022, almost 7.6 million Americans had received the updated shots. U.S. public health officials have been optimistic that Americans will get the new vaccines and have recommended that everyone ages 6 months and older receive one. About 17% of the U.S. population, or 56.5 million people, ultimately received last year's version of the vaccines.

Persons: Emily Elconin, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, U.S . Department of Health, Human Services, Pfizer, Moderna, U.S . Centers, Disease Control, Thomson Locations: Waterford , Michigan, U.S, Moderna, Novavax

The U.S. government in May ended the COVID public health emergency declaration during which it bought the shots and provided them to all Americans for free. In the current privatized system, health insurance plans by law must cover the shots at no cost. McKesson (MCK.N), one of the largest U.S. wholesalers, said it has distributed over 3.8 million shots so far. "Health insurance providers continue to educate Americans about where and how to get their COVID vaccines within their plan’s coverage," David Allen, a spokesperson for insurance lobby group AHIP said. Now that the government is no longer footing the bill for their vaccine supply, pharmacy owners need to pay for the shots.

Persons: Kate MacDowell, MacDowell, Kaiser, David Allen, AHIP, David Kohll, James Daily, he's, Suzanne Berman, Michael Erman, Ahmed Aboulenein, Caroline Humer, Bill Berkrot Organizations: Pfizer, U.S . Department of Health, Human Services, Kaiser Permanente, COVID, Moderna, CVS, Walmart, Walgreens, Walgreens Boots Alliance, Cardinal Health, Reuters, Kohll's Pharmacy, Thomson Locations: WASHINGTON, U.S, Portland , Oregon, Oregon, California, Nebraska, Readington , New Jersey, Crossville , Tennessee, New York, Washington

☆ Nobel Prize winner Katalin Karikó raised a two-time Olympic gold medalist: Here's her No. 1 piece of parenting advice
▼ + stars: | 2023-10-08 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +1 min

On Monday, Katalin Karikó won the Nobel Prize in Physiology and Medicine. Her research with Drew Weissman, with whom she shares the prize, laid the foundation for the Covid-19 vaccines developed by BioNTech-Pfizer and Moderna. During her time at the University of Pennsylvania she had trouble securing grant funding and bounced from lab to lab. "When I was doing the research I could see the promise," she tells CNBC Make It. She holds an undergraduate and masters degree from the University of Pennsylvania and an MBA from the University of California, Los Angeles.

Persons: Katalin Karikó, Drew Weissman, Susan Francia Organizations: Medicine, BioNTech, Pfizer, Moderna, Karikó's, University of Pennsylvania, CNBC, University of California Locations: Los Angeles

☆ Nobel Prize winner Katalin Karikó was 'demoted 4 times' at her old job. How she persisted: 'You have to focus on what's next'
▼ + stars: | 2023-10-06 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +6 min

On Monday, Karikó, along with her collaborator Drew Weissman, won the Nobel Prize in Physiology and Medicine. It's clear, and impressive, that Karikó didn't take those obstacles personally. Suhadolnik didn't receive the news well, she says. If you have a Ph.D. from an American Ivy League [university], that's better compared to if you have a degree from a foreign university." The type of work Karikó does, Feigl-Ding says, doesn't make splashy headlines, because groundbreaking work rarely does.

Persons: Pfizer Covid, Katalin, Drew Weissman, Karikó, didn't, Robert J, Suhadolnik, Susan, Suhadolnik didn't, Gregory Zuckerman's, I'm, wasn't, Eric Feigl, Ding, doesn't, Nobel, Albert Einstein didn't, Ding epidemiologist, Weissman Organizations: Pfizer, Moderna, CNBC, University of Pennsylvania, University of Szeged, Biological Research, Temple University, Uniformed Services University of, Health Sciences, New, Systems Institute, Harvard Medical School, American Ivy League, Universities, Systems, Harvard Medical Locations: Hungary, Philadelphia, Bethesda , Maryland, UPenn, United States, U.S, New England

☆ Moderna combination Covid, flu vaccine moves to final stage trial after positive data
▼ + stars: | 2023-10-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study. The trial evaluated the combination shot in two different age groups: people 50 to 64 years of age and participants 65 to 79. The safety data of mRNA-1083 was similar to that of the stand-alone Covid shot, according to Moderna. No new safety concerns were identified with the combination vaccine. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV.

Persons: Stéphane Bancel, BioNTech Organizations: Moderna, Pfizer, GlaxoSmithKline Locations: Moderna

A vial labelled "Novavax COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Maryland-based company, whose COVID vaccine is its lone marketed product, has adopted cost-cutting measures and is counting on commercial sales of its updated shot to help it stay afloat. The CDC's Advisory Committee on Immunization Practices (ACIP) will not meet again to discuss the Novavax shot, a spokesperson said. Novavax's original COVID shot received U.S. authorization in July 2022, long after Pfizer and Moderna vaccines were in use. All three of the updated shots target the XBB.1.5 variant of the coronavirus.

Persons: Dado Ruvic, BioNTech, COVID, John Jacobs, Jacobs, Sriparna Roy, Bill Berkrot Organizations: REUTERS, U.S . Food, Drug Administration, U.S . Centers for Disease Control, Prevention, Pfizer Inc, Moderna, FDA, Pfizer, Moderna's, Thomson Locations: U.S, Maryland, Bengaluru

CNN —This year’s Nobel Prize in physiology or medicine has been awarded to Katalin Karikó and Drew Weissman for their work on mRNA vaccines, a crucial tool in curtailing the spread of Covid-19. The Nobel Prize committee announced the prestigious honor, seen as the pinnacle of scientific achievement, in Sweden on Monday. Rickard Sandberg, a member of the Nobel Prize in medicine committee, said, “mRNA vaccines together with other Covid-19 vaccines have been administered over 13 billion times. They sold their car, Karikó told The Guardian, and stuffed the money – an equivalent of about $1,200 – in their daughter’s teddy bear for safekeeping. Weissman told CNN that their technology is much more efficient than traditional methods of producing vaccines.

Persons: Katalin Karikó, Drew Weissman, “, Karikó, Weissman, Rickard Sandberg, ” Karikó, Steffen Trumpf, BioNTech, Penn Medicine J, Larry Jameson, . Weissman, ” Jameson, Drew, ”, Hope, I’m Organizations: CNN, University of Pennsylvania, Pfizer, Penn Medicine, UPenn’s School of Medicine, Kati, Temple University, Guardian, Moderna Locations: Covid, Sweden, Hungarian, American, Germany, Norway, Hungary, United States, Philadelphia, UPenn

The Nobel Prize in Medicine was awarded Monday to two scientists whose work led to the mRNA vaccines against COVID-19. As countries prepared to roll out those shots, The Associated Press took a look at how the vaccines were developed so quickly. ___How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped -- over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted. Both shots — one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health — are so-called messenger RNA, or mRNA, vaccines, a brand-new technology.

Persons: Dr, Anthony Fauci, Buddy Creech, ” Creech, Tal Zaks, ”, Drew Weissman, Weissman, Katalin, Philip Dormitzer, Barney Graham’s, ” Fauci, Graham, Jason McLellan, hadn't, “, ” Graham, Germany’s, Pfizer’s Dormitzer, Ugur Sahin Organizations: Medicine, COVID, Associated Press, Vanderbilt University, Infectious Diseases Society of America, Pfizer, BioNTech, Moderna, National Institutes of Health, NIH, University of Pennsylvania, Penn, NIH’s Vaccine Research Center, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Department of Science Education, AP Locations: U.S, Massachusetts, BioNTech, New York, China

☆ Covid-induced Nobel Prize is on brand
▼ + stars: | 2023-10-02 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

They realized that modifying lab-made mRNA, a molecule used for protein production, nearly stopped the body from mounting an inflammatory response. It takes, on average, about 25 years between publishing work and receiving the Noble Prize in medicine. There are exceptions: insulin was created in 1921, administered to children in 1922, and the inventors were given the prize in 1923. Contrast that to Ralph Steinman, awarded the prize in Medicine in 2011 for work done in 1973. Follow @rob_cyran on XCONTEXT NEWSKatalin Kariko and Drew Weissman were awarded the Nobel Prize in Medicine on Oct. 2 for their work in a paper published in 2005 in the journal Immunity on mRNA molecule modifications.

Persons: Kariko, Drew Weissman, Ralph Steinman, Germany’s, Weissman, Lauren Silva Laughlin, Aditya Sriwatsav Organizations: Reuters, University of Pennsylvania, Medicine, U.S . Defense Department, Pfizer, Moderna, Thomson Locations: Covid

And I told her that many, many scientists work very, very hard," Kariko added. BioNTech said in June that about 1.5 billion people across the world had received its mRNA shot, co-developed with Pfizer (PFE.N). [1/11]Katalin Kariko and Drew Weissman win the 2023 Nobel Prize in Physiology or Medicine at the Karolinska Institute in Stockholm, Sweden October 2, 2023. The medicine prize kicks off this year's Nobel awards with the remaining five to be unveiled in coming days. The prizes, first handed out in 1901, were created by Swedish dynamite inventor and wealthy businessman Alfred Nobel.

Persons: Weissman, Katalin Kariko, Drew Weissman, Kariko, BioNTech, Rickard Sandberg, Susan Francia, immunologist, ”, Sir Andrew Pollard, Alfred Nobel, Swede Svante Paabo, Alexander Fleming, Karl Landsteiner, Niklas Pollard, Johan Ahlander, Ludwig Burger, Terje Solsvik, Andrew Cawthorne Organizations: Medicine, Nobel, Sweden's Karolinska Institute, University of Szeged, University of Pennsylvania, Pfizer, Karolinska Institute, TT News Agency, REUTERS Acquire, Boston University, Oxford University, AstraZeneca, Moderna, Thomson Locations: STOCKHOLM, COVID, Hungary, Pennsylvania, Szeged, U.S, Stockholm, Sweden, Frankfurt, Krisztina, Budapest, Oslo

☆ Schott Pharma shares climb in Frankfurt debut
▼ + stars: | 2023-09-28 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Schott Pharma debuted on the Frankfurt stock exchange on Thursday at 30 euros per share, trading well above analyst expectations. Shares of the company were up 10% in the first minutes. Schott Pharma said sales were up 8.4% year-on-year for the first nine months of the 2023 fiscal year, hitting 670 million euros ($704 million) over the period. Schott Pharma has production and sales units across 33 countries. The Schott Pharma IPO is only the third new listing on the Frankfurt stock exchange this year and is expected to be the largest.

Persons: Andreas Reisse Organizations: Schott Pharma, Moderna Locations: Frankfurt

☆ Europe to decide on Novavax's COVID vaccine in October
▼ + stars: | 2023-09-21 | by ( ) www.reuters.com time to read: +1 min

Four vials with the "Nuvaxovid" COVID-19 vaccine from Novavax are pictured in Saabruecken, Germany, February 26, 2022. REUTERS/Frank Simon/File photo Acquire Licensing RightsSept 21 (Reuters) - The European Medicines Agency (EMA) expects to decide on the use of Novavax's (NVAX.O) updated COVID-19 vaccine in October, its director Emer Cooke said on Thursday. The agency had started the evaluation process for the protein-based shot on Aug. 24, Cooke said at a press conference. EU regulators recently gave the green light for an updated COVID-19 vaccine from Pfizer (PFE.N) and its German partner BioNTech (22UAy.DE), which targets the XBB.1.5 variant of Omicron. Moderna's (MRNA.O) updated shot is also on track to win approval.

Persons: Frank Simon, Emer Cooke, Cooke, BioNTech, Novavax, Bhanvi, Michael Erman, Saumyadeb Chakrabarty Organizations: REUTERS, European Medicines Agency, Pfizer, U.S . Food, Drug Administration, FDA, Moderna, Thomson Locations: Saabruecken, Germany, United States, Bengaluru, New York

☆ Meet the Black students who were instrumental in developing the first Covid-19 shots
▼ + stars: | 2023-09-15 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +10 min

Among about two dozen scientists in Graham’s lab were three young students: Olubukola Abiona, Geoffrey Hutchinson and Cynthia Ziwawo. What the world didn’t know at the time was that those three students — Abiona, Hutchinson and Ziwawo — were doing the foundational work for those vaccines to eventually save lives. Geoffrey Hutchinson served in the Peace Corps and taught chemistry to high school students in Mozambique. The fruits of Abiona, Hutchinson and Ziwawo’s labor were evident this week as the United States began to roll out updated versions of the Moderna and Pfizer/BioNTech Covid-19 vaccines. Abiona, Hutchinson and Ziwawo all confirmed Wednesday that although they haven’t made their appointments yet, they plan to get the updated shots.

Persons: Barney Graham’s, Olubukola Abiona, Geoffrey Hutchinson, Cynthia Ziwawo, “, Graham, ‘, ’ ”, Hutchinson, ”, ” Ziwawo, Anthony Fauci, — Abiona, Ziwawo —, Ziwawo, Kizzmekia Corbett, ” Corbett, David Satcher, he’s, Valerie Montgomery Rice, “ They’re, Abiona, Hannah Montana, Austin Steele, CNN Abiona, BioNTech, “ It’s, Dr, Sanjay Gupta Organizations: CNN, Vaccine Research, National Institutes of Health, University of Washington, “, Vaccine Research Center, National Institute of Allergy, Diseases, Moderna, Morehouse School of Medicine, David Satcher Global Health Equity Institute, Association of American Medical Colleges, NIH, Disney, David Satcher Global Health Equity Summit, KPMG LLP, Indiana University School of Medicine, Case Western Reserve University, Peace Corps, United States, Pfizer, CNN Health, FDA, Food and Drug Administration, US Centers for Disease Control Locations: China, Bethesda , Maryland, Ziwawo, United States, Atlanta, Graham’s, Nigeria, Mozambique, Abiona, United

The nationwide online poll, which concluded on Thursday, showed that almost 30% of respondents were very interested in getting the vaccine and another 24% were somewhat interested. U.S. public health officials earlier this week recommended updated COVID-19 vaccines from Pfizer (PFE.N)/BioNTech (22UAy.DE) and Moderna (MRNA.O) that target a recently circulating Omicron variant of the coronavirus. Almost 42% said they were mainly interested in getting the vaccine to reduce their risk of severe illness. During the last revaccination campaign, when most Americas had either already had the COVID virus or been previously vaccinated, only around 56.5 million people got the updated booster shots, CDC data shows. The Reuters/Ipsos poll was conducted online and nationwide between Sept. 8 and Sept. 14, gathering responses from 4,413 U.S. adults.

Persons: Adam Berman, Michelle Chester, Ron DeSantis, Jesse Goodman, Ahmed Aboulenein, Jason Lange, Michael Erman, Jennifer Rigby, Scott Malone, Leslie Adler Organizations: Jewish Medical Center, Northwell Health, Reuters, U.S . Centers for Disease Control, Pfizer, Moderna, Republicans, Republican, Wednesday, Georgetown University, U.S . Food, Drug Administration, Thomson Locations: Long, New Hyde Park , New York, WASHINGTON, United States, ., U.S, Americas, Washington, New York, London

☆ US CDC Expects 'Tripledemic' Hospitalizations to Remain High This Year Vs Pre-Pandemic Levels
▼ + stars: | 2023-09-14 | by ( Sept. | At P.M. | ) www.usnews.com time to read: +1 min

(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said on Thursday it expects the total number of hospitalizations from COVID-19, respiratory syncytial virus infections and flu this year to be similar to last year, higher than pre-pandemic levels. The government health agency also said it expects flu and RSV infections to increase over the fall and winter seasons. Vaccines for all three major respiratory viruses – COVID-19, flu, and RSV – will be available this fall, the CDC said. Higher levels of vaccination across the population will help reduce the number of hospitalizations and risk of straining the country's hospitals, CDC added. A surge in cases of RSV infections coinciding with an increase in COVID transmission and an earlier-than-normal flu season has raised the specter of a so-called 'tripledemic' of respiratory illness across the United States.

Persons: Mariam Sunny, Shailesh Kuber Organizations: Reuters, U.S . Centers for Disease Control, Prevention, CDC, Pfizer Locations: COVID, United States, Bengaluru

☆ ICON to partner with US govt agency to test COVID vaccine candidates
▼ + stars: | 2023-09-13 | by ( ) www.reuters.com time to read: +1 min

Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsCompanies Icon Plc FollowBioNTech SE FollowModerna Inc Follow Show more companiesSept 13 (Reuters) - Contract research firm ICON Plc (ICLR.O) said on Wednesday it is partnering with the U.S. government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates. As part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots. The U.S. agency will select the vaccine candidate for the trial. The U.S. Food and Drug Administration on Monday authorized updated COVID-19 vaccines from Pfizer (PFE.N)/BioNTech (22UAy.DE) and Moderna (MRNA.O) that target the XBB.1.5 subvariant of the virus.

Persons: Dado Ruvic, Pratik Jain, Saumyadeb Chakrabarty, Shounak Organizations: REUTERS, U.S, Research, Development Authority, U.S . Food, Drug Administration, Pfizer, Moderna, Thomson Locations: U.S, Bengaluru

☆ US pharmacy chains gear up to administer updated COVID shots
▼ + stars: | 2023-09-13 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Kamil Krzaczynski/File Photo Acquire Licensing RightsSept 13 (Reuters) - Drugstore chains CVS Health (CVS.N) and Walgreens Boots Alliance (WBA.O) said on Wednesday that updated COVID-19 vaccines would be available at their stores as soon as this week. The U.S. Centers for Disease Control and Prevention (CDC) director on Tuesday signed off on broad use of updated COVID-19 vaccines, arming a push to align the next round of shots more closely with the circulating variant of the virus, much like annual flu shots are designed. The U.S. Food and Drug Administration has approved an updated vaccine made by Pfizer (PFE.N) and its German partner BioNTech (22UAy.DE) as well as one by Moderna (MRNA.O) for people ages 12 and above. The agency has also authorized the shots for emergency use in children ages 6 months through 11 years. Walgreens said it would start taking appointments for the updated vaccines from Monday, but could begin earlier appointments as stores receive vaccines this week.

Persons: Luis S, Solano, Victor Walchirk, Kamil Krzaczynski, BioNTech, Christy Santhosh, Devika Organizations: Pfizer, Victor, REUTERS, Walgreens Boots Alliance, U.S . Centers for Disease Control, Prevention, U.S . Food, Drug Administration, Moderna, Walgreens, Rite, CVS, Retail, Walmart, Thomson Locations: Evanston , Illinois, U.S, Bengaluru

The updated shots are part of a push by public health officials to align the next COVID vaccines more closely with the actual circulating variant of the virus, similar to the way annual flu shots are designed. The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID vaccines made by Pfizer (PFE.N) and its German partner BioNTech SE (22UAy.DE) as well as by Moderna (MRNA.O). CDC Director Mandy Cohen is expected to approve the recommendations issued by the advisers, allowing Americans to get the updated vaccines. The first COVID vaccines in 2020 were monovalent, or single-target vaccines, aimed at the original strain of the virus. They were followed by bivalent COVID vaccine booster shots that targeted both the original and the Omicron strains.

Persons: Emily Elconin, BioNTech, Caitlin Rivers, Mandy Cohen, Rivers, bivalent, Daniel Kuritzkes, Eris, Kuritzkes, Novavax, Bhanvi, Julie Steenhuysen, Will Dunham, Caroline Humer Organizations: REUTERS, U.S . Centers for Disease Control, Prevention, U.S . Food, Drug Administration, Pfizer, Moderna, FDA, Johns Hopkins Center for Health Security, CDC, Omicron, Brigham, Women's Hospital, Vaccine, EG, Thomson Locations: Waterford , Michigan, U.S, United States, Baltimore, Europe, Asia, Boston, Moderna, Bengaluru, Chicago

☆ COVID vaccine manufacturers set list price between $120-$130 per dose
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +1 min

A patient receives their coronavirus disease (COVID-19) vaccine booster during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin/File photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesSept 12 (Reuters) - U.S. COVID vaccine manufacturers set list prices for their shots between $120 and $130 per dose, company executives said at an advisory panel meeting of U.S. Centers for Disease Control and Prevention on Tuesday. Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) set the list price at $120 per dose, while Moderna (MRNA.O) said the list price for its shot is $129 per dose, for their respective COVID vaccines. Novavax (NVAX.O) said the list price for its COVID vaccine was $130 per dose. Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Emily Elconin, BioNTech, Bhanvi Satija, Sriparna Roy, Shounak Dasgupta Organizations: Pfizer, REUTERS, U.S . Centers for Disease Control, Moderna, Thomson Locations: Southfield , Michigan, U.S, Bengaluru

WASHINGTON (AP) — The U.S. approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and blunt any surge this fall and winter. It’s part of a shift to treat fall updates of the COVID-19 vaccine much like getting a yearly flu shot. A CDC advisory panel is set to issue recommendations Tuesday on who most needs the updated shots. The FDA pointedly isn’t calling this latest round a “booster” but instead a vaccine updated to better match the currently circulating virus. But while the FDA's decision allows for wide use of the updated shots, the CDC will decide how strongly different groups are urged to get them.

Persons: BioNTech, they’ve, There’s, Novavax, It’s, Peter Marks Organizations: WASHINGTON, Drug Administration, Moderna, Pfizer, Disease Control, CDC, FDA, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP

Search resuls for: "BioNTech"

25 mentions found